United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - methyldopa anhydrous - oral tablet - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - paracetamol; pseudoephedrine hydrochloride; pholcodine - capsule, hard - 500 mg/30 mg/5 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - paracetamol; phenylephrine hydrochloride; guaifenesin - capsule, hard - 500 mg/6.1 mg/100 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - methyldopa (anhydrous) - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - methyldopa (anhydrous) - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

c p pharmaceuticals ltd - methyldopa (anhydrous) - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - methyldopa (anhydrous) - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - methyldopa (anhydrous) - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - methyldopa (anhydrous) - oral tablet - 500mg

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 25 mg - carbidopa and levodopa tablets are indicated in the treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. this product is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin b6 ). in some patients a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. however, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from carbidopa and levodopa. although the administration of carbidopa permits control of parkinsonism and parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial othe